Chairman of the Board Hans Peter Bøhn (Born 1955)
Hans Peter Bøhn is a Norwegian citizen with a medical degree. He started his pharmaceutical industry career as medical adviser in Nycomed Imaging. Over the ensuing 12 years he gained broad experience from management positions in the pharmaceutical industry within drug safety, international marketing and operations and clinical research as well as gaining a post-graduate Diploma of Pharmaceutical Medicine. After the years in the industry he joined Fondsfinans as a financial analyst covering the life science sector. From 2012 he has been manager of the non-profit “Svanhild og Arne Musts Fond for Medisinsk Forskning” as well as serving as an independent adviser to among others the Research Council of Norway, the Norwegian Cancer Society, Innovation Norway, Oslo Cancer Cluster as well as a number of biotech start-up companies. He has been a Board member of PCI Biotech Holding ASA since 2015.
Board member Professor Kjetil Taskén, MD, PhD (Born 1965)
Dr. Taskén holds an MD and a PhD degree from University of Oslo (UiO) and is authorised to practice as a physician in Norway. Dr. Taskén is Professor of Medicine at UiO since 2001. He is also Director of the Biotechnology Centre of Oslo, UiO, and of Centre for Molecular Medicine Norway, Nordic EMBL Partnership, UiO. He was co-founder and Board member of Lauras AS, where he also was VP R&D for almost 10 years. Dr. Taskén has previously served as Board member of Biomedical Innovation AS and siRNAsense AS. He has been a Board member of PCI Biotech Holding ASA since 2008.
Board member Dr. Hilde Hermansen Steineger, PhD (Born 1966)
Dr. Steineger holds a PhD in Medical Biochemistry from the University of Oslo, Norway. She previously served as Strategic Innovation Management Nutrition & Health in BASF, and previously served as Head of Innovation Management of Pronova BioPharma AS/ BASF. Dr. Steineger has held positions as VP IR & Communications at Pronova BioPharma, as Senior Associate with Neomed Management, and as equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen. She has also worked as an independent advisor focusing on start-ups in Life Science/Health Care. Dr. Steineger is currently a Board member at Strongbridge Biopharma plc and Nordic Nanovector ASA. She has been a Board member of PCI Biotech Holding ASA since May 2014.
Board member Dr. Christina Herder, PhD (Born 1961)
Dr. Herder is the CEO of Modus Therapeutics AB, a Swedish drug development company, since 2014. She has over 20 years of experience from the life science industry, both from the areas of drug development as well as business development. Previous positions include Sobi, where she built up the portfolio management function and worked with Corporate Development. She holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Dr. Herder has previously served as Board member of Akinion Pharmaceuticals AB. She has been a Board member of PCI Biotech Holding ASA since 2015.
Board member Lars Viksmoen, MD, (Born 1949)
Dr. Viksmoen is Norwegian citizen and MD from University of Oslo, Norway. After 10 years as surgeon he started his professional life in the pharma industry at the Norwegian subsidiary of Merck & Co. Inc. in 1990. During the last 25 years he has gained a broad international experience through several international management and executive roles within the pharma, biotech as well as medtech industry. His main responsibilities and capabilities have been within commercialization of innovation, i.e. managing and leading commercial focused business unites and organisations. In addition, he has over the last close to 10 years broad experience leading listed companies. His last position has been as President and CEO of GN ReSound AS, Denmark, the fourth largest hearing-aid manufacture worldwide, listed in Denmark. Currently, he works part time as special strategic advisor at GN Store Nord A/S. He became a Board member of PCI Biotech Holding ASA in May 2016.